AChE antibody
- Known as:
- AChE (anti-)
- Catalog number:
- 10-1882
- Product Quantity:
- 200 ul
- Category:
- -
- Supplier:
- Fitzgerald
- Gene target:
- AChE antibody
Related genes to: AChE antibody
- Gene:
- ACHE NIH gene
- Name:
- acetylcholinesterase (Cartwright blood group)
- Previous symbol:
- YT
- Synonyms:
- -
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-02
- Date modifiied:
- 2019-04-23
Related products to: AChE antibody
Related articles to: AChE antibody
- The interaction between gene mutations and epitranscriptomic alterations in colorectal cancer (CRC) remains poorly understood. Here, we identified that KRAS mutations, present in ∼40%-50% of CRC patients, act as driver mutations mediating an aberrant epitranscriptome. In human CRC patients, mutant KRAS correlates with increased mA mRNA modification. In isogenic CRC cells and animal models expressing wild-type KRAS or mutant KRAS, mA modification was upregulated in mutant KRAS cells/mice. Mutant KRAS promotes mA modification by stabilizing METTL3 protein, an mA writer, through inhibiting its degradation via p62-driven selective autophagy. Integrative RNA-seq, mA-seq, and RIP-seq revealed BCL9L as a target of mutant KRAS-mediated mA. Mutant KRAS promotes METTL3-dependent BCL9L mA modification and YTHDF1-dependent translation, leading to elevated BCL9L translation and protein expression. Mechanistically, the METTL3-mA-BCL9L axis promotes secretion of TGF-β1/β2/β3 to enrich immunosuppressive T in the tumor microenvironment. BCL9L knockout thus significantly impaired KRAS-mutant CRC growth in murine allograft models and human xenografts in CD34 immunohumanized mice, concomitant with T suppression and Th1 activation. Finally, we demonstrated that pharmacological blockade of METTL3 by STC-15 or STM2457 synergized with mutant KRAS inhibitors to inhibit KRAS-mutant CRC growth in mouse models, indicating a promising strategy to boost the efficacy of KRAS inhibitors in KRAS-mutant CRC. - Source: PubMed
Publication date: 2026/09/09
Chen DanyuHuang PingmeiTao RuizhiJi FenfenWei QinyaoKo Lok HinZhou LianxinChen HuarongCheung AlvinKang WeiTo Ko FaiYu JunWong Chi Chun - Opioid use disorder (OUD) is a severe public health crisis in the Americas. This study aimed to comprehensively evaluate the spatiotemporal trends, socioeconomic inequalities, and future projections of the OUD burden across the region from 1990 to 2050. - Source: PubMed
Publication date: 2026/09/09
Hu QianhuiLi YanWu ZhengjunWang Zhaohui - BACKGROUND Bronchogenic cysts (BCs) are rare congenital anomalies that are extremely uncommon in the retroperitoneum; in this uncommon anatomical location, they are frequently misdiagnosed radiologically as solid adrenal or pancreatic tumors. This report aims to enhance clinical awareness and diagnostic vigilance regarding ectopic retroperitoneal bronchogenic cysts (ERBCs) that closely mimic other common endocrine or urological entities. CASE REPORT We report a case of a middle-aged man presenting with recurrent right flank pain. Abdominal computed tomography (CT) demonstrated multiple right renal calculi with mild hydronephrosis and a well-defined, homogeneous nodular lesion in the right adrenal region. Notably, the lesion exhibited a high unenhanced density (mean 48.79 HU), mimicking a solid adrenal neoplasm. Following comprehensive hormonal and biochemical evaluations, a multidisciplinary team determined that a retroperitoneal tumor could not be ruled out. The patient subsequently underwent laparoscopic resection of the retroperitoneal mass combined with right ureteral stent placement. Intraoperative exploration revealed a morphologically regular adrenal gland and a separate 4×2.5×1.5 cm oval mass located on the psoas major muscle. Histopathological examination confirmed the diagnosis of a benign bronchogenic cyst, characterized by a cyst wall containing prominent cartilaginous components, smooth muscle, and a lining of pseudostratified ciliated columnar epithelium. The patient recovered uneventfully, with complete symptom resolution. CONCLUSIONS ERBCs should be included in the differential diagnosis of non-functional lesions in the periadrenal region, especially when atypical high CT attenuation creates diagnostic ambiguity. Minimally invasive laparoscopic excision remains the gold standard for management. - Source: PubMed
Publication date: 2026/09/10
Luo JieQin Ruixiang - To determine the prevalence and clinical characteristics of facial pain in patients with primary hemifacial spasm (HFS), identify factors associated with its occurrence, and evaluate its longitudinal course following botulinum toxin type A (BoNT-A) treatment. - Source: PubMed
Publication date: 2026/09/09
Soares Miriam CarvalhoSilva Mariana de Almeida CruzFranco Clélia Maria RibeiroSampaio Rocha-Filho Pedro Augusto - Aspirin has been used to treat pain and fever for 120 years. Its uses expanded into treating arthritis and prevention of thrombotic events. Its anti-cancer role emerged with observational studies in the 1980's and subsequent cancer review in those treated with aspirin in cardiovascular trials. Two randomised placebo-controlled trials with cancer as an endpoint, the Women's Health Study and CAPP2 provided support. The latter involved 861 carriers of Lynch syndrome (LS) who received either 600 mg aspirin or placebo for 2-4 years. Aspirin recipients subsequently had 50% fewer colorectal cancers. CaPP3 randomised 1866 LS carriers to 600 mg, 300 mg or 100/75 mg daily for 2 years blinded then for 3 years open label. Lynch syndrome cancer and colorectal cancer rate mirrored that in the 600 mg limb of CAPP2. Those on the lowest dose had the fewest cancers in keeping with this being equivalent to 600 mg. The Intention to treat confidence intervals fell within the predefined upper limit of 1.5. A survey of primary care doctors revealed only 62% would agree to prescribe the 600 mg dose regardless of guidance. As a normal dietary component, salicylate is likely to influence multiple pathways. Most interesting is the recent demonstration that low dose aspirin blocks release of thromboxane A2, a product of activated platelets which suppresses T cell function. An international Delphi report has endorsed the daily use of 75-100 mg aspirin in adults with Lynch syndrome prior to old age when adverse effects become a greater concern. - Source: PubMed
Publication date: 2026/09/09
Burn JohnBishop D Timothy